Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6 versus 12 cycles of adjuvant temozolomide in malignant astrocytoma
IRCT20160706028815N3Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Mar 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of temozolomide in glioblastoma (GBM) and anaplastic astrocytoma (AA) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: overall survival and progression-free survival. Started Mar 2018; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on IRCT20160706028815N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160706028815N3.